- IL-17 inhibitors in psoriasis treatment2022 | Third Faculty of Medicine
- Ideal patient for IL-17 inhibitors treatment2022 | First Faculty of Medicine
- Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry2022 | First Faculty of Medicine, Third Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Pilsen
- Efficacy of switches within the class of IL-17 inhibitors: An analysis of data from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy (BIOREP)2022 | First Faculty of Medicine, Third Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Pilsen
- Long-term outcomes of ixekizumab treatment in patients with axial spondyloarthritis2023 | First Faculty of Medicine
- Highly active form of psoriatic arthritis on top of pemphigus vulgaris and its successful treatment with secukinumab2018 | First Faculty of Medicine
- Current treatment options for spondyloarthritits2018 | First Faculty of Medicine
- Invasive aspergillus infection of middle ear in a patient treated with secukinumab, methotrexate and corticosteroids for psoriasis and psoriatic arthritis2022 | Second Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Psoriatic arthritis news2019 | First Faculty of Medicine
- Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study2021 | Third Faculty of Medicine
- Real-world Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients with Psoriatic Arthritis in Thirteen European Countries2022 | First Faculty of Medicine
- Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study2022 | Third Faculty of Medicine